Arcutis: Dermatology Revenue Is Turning into a Compounding Growth Engine
Arcutis is transitioning from pure R&D to a commercial growth story. ZORYVE posted $105.4M in Q1 2026 revenue (65% YoY) and management reaffirmed 2026 guidance of $480-495M. With pediatric label expansion, new formulations and a broader sales effort, the business is starting to compound. The setup favors a long trade with defined risk controls whil…